Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Close of $26 Million Funds Immunomodulation Candidate AX-158 Development Adds New Investors Eli Lilly and Company and Sound Bioventures – CAMBRIDGE, Mass., May 11, 2022 /PRNewswire/ — Artax Biopharma, Inc., a clinical stage biotechnology company focused on transforming the treatment of T…
Comments Off on Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases